ClinicaliQ Trial Snapshot
- Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status — Active Not Recruiting • Phase II • NCT05673187.
- Adagrasib showed benefit in elderly or unfit lung cancer patients with KRASG12C mutations who couldn't tolerate standard treatments.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
ADEPPT is an international, multicentre, single-arm phase II trial. The protocol treatment consists of adagrasib, which is administered at a dose of 600 mg orally, twice daily until progression or unacceptable toxicity.The primary objective of this trial is to assess the clinical efficacy of adagrasib treatment, in terms of objective response, in patients with KRASG12C-mutant NSCLC, including the elderly (≥70 years) or patients with poor performance status (ECOG PS=2). Conditions: NSCLC Stage IV, KRAS P.G12C Interventions: Adagrasib Lead Sponsor: ETOP IBCSG Partners Foundation Planned Enrollment: 68 participants